by Payash Bahuguna | Mar 9, 2023 | PR
Iktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutions Iktos announces the closing of a € 15.5m Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation...
by Payash Bahuguna | Nov 23, 2022 | PR
Iktos announces a collaboration with Medicines for Malaria Venture (MMV), a leading product development partnership (PDP) in the field of antimalarial drug research and development. Under this collaboration agreement, Iktos will apply its new ‘DockAI’ technology to...
by Payash Bahuguna | Jun 28, 2022 | PR
Iktos announces a collaboration deal with Galapagos, a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, to apply Iktos’s generative modeling artificial intelligence (AI) technology in one of...
by Payash Bahuguna | Jun 21, 2022 | PR
Iktos today announced a research collaboration with Zealand Pharma A/S, a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design. Follow the link for the full press...
by Payash Bahuguna | May 10, 2022 | PR
Iktos and Sygnature Discovery announce their collaboration in Artificial Intelligence for de novo drug design. Under the 3-year agreement, Sygnature will deploy Iktos’s de novo generative design software Makya™, which will be used by Sygnature scientists to...
by Payash Bahuguna | Apr 5, 2022 | PR
Iktos and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, announce a strategic collaboration agreement in Artificial Intelligence for new drug design....
